TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an update.
Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing vaccines, including its proprietary RSV vaccine candidate SCB-1019, aimed at addressing respiratory health needs.
Average Trading Volume: 1,448,367
Technical Sentiment Signal: Hold
Current Market Cap: HK$337.2M
Learn more about 2197 stock on TipRanks’ Stock Analysis page.